Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [11C]UCB-J positron emission tomography study
Converging lines of evidence implicate synaptic loss in cognitive impairment associated with schizophrenia. However, it remains unknown whether synaptic terminal density and premorbid intellectual functioning are related in vivo, or whether there are age-related changes in them in schizophrenia. To address this, we investigated whole brain grey matter synaptic vesicle glycoprotein 2A (SV2A) levels and examined their relationship with intellectual functioning and age, in forty-three patients with schizophrenia (SCZ) and 26 healthy volunteers (HV), using [<sup>11</sup>C]UCB-J positron emission tomography (PET). Whole brain grey matter [<sup>11</sup>C]UCB-J distribution volume ratio (DVR) was significantly lower in the SCZ than the HV group (Cohen's d = 0.64, p = 0.01), and negatively correlated with age in both groups (Spearman's rho = -0.46 to -0.55), with no significant group difference in magnitude of DVR-age correlations (z = 0.44, p = 0.66). Current (Cohen's d = 0.73) and premorbid IQ (Cliff's delta = 0.37) were significantly lower in the SCZ than the HV group, though DVR was not significantly associated with current or premorbid IQ in either group (including in chronic medicated and early-course unmedicated SCZ subgroups). The group differences in DVR are consistent with a global deficit in synaptic terminal density in schizophrenia, with similar age-related changes in people with schizophrenia and healthy volunteers. The lack of significant relationships between DVR and premorbid or current cognitive measures are not consistent with the hypothesis that lower levels of synaptic terminal density observed in schizophrenia underlie lower levels of intellectual functioning in the disorder.
Authors
- Ekaterina Shatalina (ORCID: https://orcid.org/0000-0001-8900-0792)
- Nikola Rahaman
- Ellis Chika Onwordi (ORCID: https://orcid.org/0000-0001-8108-1225)
- Maja Ranger
- Thomas Whitehurst (ORCID: https://orcid.org/0000-0002-7005-902X)
- Sridhar Natesan (ORCID: https://orcid.org/0000-0001-7499-1714)
- Martin Osugo (ORCID: https://orcid.org/0000-0002-5462-8464)
- Ayla Mansur (ORCID: https://orcid.org/0000-0002-2512-5745)
- Atheeshaan Arumuham
- Steve M. Church
- Roger N. Gunn
- Tiago Reis Marques
- Abraham Reichenberg
- Oliver D. Howes
- Ravi Mehrotra
- Eugenii A. Rabiner
Institutions
- Wellcome Centre for Human Neuroimaging (GB)
- King's College London (GB)
- South London and Maudsley NHS Foundation Trust (GB)
- Central and North West London NHS Foundation Trust (GB)
- Chelsea and Westminster Hospital NHS Foundation Trust (GB)
- East London NHS Foundation Trust (GB)
- West Middlesex University Hospital (GB)
- Hammersmith Hospital (GB)
- IQVIA (United Kingdom) (GB)
- Invicro (United Kingdom) (GB)
- West London Mental Health NHS Trust (GB)
- MRC London Institute of Medical Sciences (GB)
- Imperial College London (GB)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Neuropsychopharmacology
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1038/s41386-026-02349-7
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00